GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Gross Profit

Dechra Pharmaceuticals (LSE:DPH) Gross Profit : £426.3 Mil (TTM As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Gross Profit?

Dechra Pharmaceuticals's gross profit for the six months ended in Jun. 2023 was £210.1 Mil. Dechra Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was £426.3 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Dechra Pharmaceuticals's gross profit for the six months ended in Jun. 2023 was £210.1 Mil. Dechra Pharmaceuticals's Revenue for the six months ended in Jun. 2023 was £384.1 Mil. Therefore, Dechra Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was 54.70%.

Dechra Pharmaceuticals had a gross margin of 54.70% for the quarter that ended in Jun. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Dechra Pharmaceuticals was 57.08%. The lowest was 53.35%. And the median was 56.21%.


Dechra Pharmaceuticals Gross Profit Historical Data

The historical data trend for Dechra Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Gross Profit Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.10 291.60 345.90 384.80 426.30

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.20 188.70 196.10 216.20 210.10

Competitive Comparison of Dechra Pharmaceuticals's Gross Profit

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Gross Profit falls into.



Dechra Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Dechra Pharmaceuticals's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=761.5 - 335.2
=426.3

Dechra Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=384.1 - 174
=210.1

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £426.3 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Dechra Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=210.1 / 384.1
=54.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Dechra Pharmaceuticals  (LSE:DPH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Dechra Pharmaceuticals had a gross margin of 54.70% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Dechra Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines